Biocept Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
BIOC Nasdaq 2834 https://biocept.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Biocept Inc

Enrollment Begins in FORESEE Clinical Trial Using Biocept’s CNSide™ to Evaluate Patients with Leptomeningeal Metastases - Mar 24th, 2023 12:00 pm
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Mar 1st, 2023 1:00 pm
6 F-Rated Penny Stocks Not Worth Your Dime - Jan 31st, 2023 12:54 pm
Biocept to Explore Strategic Alternatives and Implement Restructuring Plan - Jan 6th, 2023 11:55 am
Biocept, Inc. (NASDAQ:BIOC) Q3 2022 Earnings Call Transcript - Dec 25th, 2022 5:06 pm
Biocept Reports Third Quarter 2022 Financial Results - Nov 21st, 2022 9:05 pm
Biocept Appoints Financial Executive Quyen Dao-Haddock to its Board of Directors - Nov 18th, 2022 1:00 pm
Biocept Announces Participation in an Investigator-Initiated Study to Better Understand the Development and Progression of Metastatic Breast Cancer to the Central Nervous System - Nov 16th, 2022 1:00 pm
Biocept Reports Second Quarter 2022 Financial Results - Nov 10th, 2022 9:05 pm
Biocept to Present at the LD Micro Main Event XV - Oct 19th, 2022 12:00 pm
Biocept Expands Commercial Offering of CNSide™ Assay to Most Cancers that Metastasize to the Central Nervous System - Oct 17th, 2022 12:00 pm
Biocept to Host KOL Webinar Today to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System - Oct 14th, 2022 12:00 pm
Biocept to Host Key Opinion Leader Webinar on October 14 to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System - Oct 6th, 2022 12:00 pm
Biocept Announces Receipt of Deficiency Notice from Nasdaq Regarding Requirement to Timely Quarterly Report on Form 10-Q - Aug 22nd, 2022 8:15 pm
Biocept Announces a Delay in the Filing of its Quarterly Report on Form 10-Q - Aug 16th, 2022 12:00 pm
Biocept Appoints RSM as Independent Auditor - Jun 27th, 2022 12:00 pm
Plus Therapeutics and Biocept Announce Comprehensive Laboratory Services Agreement for the ReSPECT-LM Trial - Jun 22nd, 2022 11:30 am
Biocept to Hold Business Strategy Conference Call Today - Jun 7th, 2022 12:00 pm
Biocept Reports First Quarter 2022 Financial Results - May 23rd, 2022 8:05 pm
Biocept Reports 2021 Fourth Quarter and Full Year Financial Results - Apr 6th, 2022 12:00 pm